Businesses that invest in research and development just got a reason to look closely at their New York filings. Recent federal legislation restored immediate deductibility for qualifying domestic research and experimental (R&E), also often referred to as R&D or research & development, expenditures beginning in 2025, reversing years of mandatory capitalization under Section 174. New York, however, did not follow suit.
If your company incurs R&E costs and files a New York return, the gap between federal and state treatment now requires attention.
What Changed at the Federal Level
Under prior law, businesses generally could not deduct Section 174 research expenditures in the year incurred. Instead, they were required to capitalize those costs and amortize them over several years, which pushed out tax benefits and often inflated taxable income in the near term.
Recent federal legislation reversed that requirement for domestic research activity. Starting in 2025, qualifying U.S.-based R&E expenditures can once again be deducted immediately, giving companies faster access to tax savings and improved cash flow.
For businesses concentrated in product development, engineering, software, or other research-intensive work, this is a meaningful shift in how R&E investment translates to tax outcomes.
Where New York Parted Ways
As part of its Fiscal Year 2027 Budget legislation, New York opted not to conform to the federal restoration of immediate expensing. The state established its own treatment of research expenditures instead, and that treatment applies to tax years beginning on or after January 1, 2025.
The practical effect: a research expense that’s fully deductible on your federal return this year may need a separate adjustment on your New York return. Federal and New York taxable income are no longer aligned for companies engaged in R&E activity.
Where This Creates Complexity
For businesses with New York filing obligations, the disconnect shows up in several places.
Divergent taxable income calculations. Federal and New York returns may now differ with respect to the same expenditures.
New state-specific modifications. Additional adjustments are required to reconcile the two treatments.
Heavier documentation requirements. Tracking R&E costs separately by jurisdiction becomes necessary, not optional.
More complex return preparation and projections. Estimated payments and forecasts need to account for the divergence.
Possible amended return considerations. Returns already filed for affected years may need a second look.
Technology firms, manufacturers, life sciences companies, engineering firms, and startups with substantial research spending are likely to feel this most directly, given the scale of their R&E investment relative to overall tax position.
Reviewing What’s Already Been Filed
If your business has already filed a New York return for an affected tax year, it’s worth evaluating whether an amendment is warranted under the new rules. For returns not yet filed, incorporating the required New York adjustments up front reduces the likelihood of notices or assessments down the line.
New York has also provided some relief from penalties and interest tied to these legislative changes. Whether your business qualifies depends on specific facts, so it’s important to evaluate your situation rather than make assumptions.
Building This Into Your Planning
A federal-state disconnect like this rewards businesses that plan ahead rather than react to it. Companies with ongoing research activity should consider:
Reviewing Section 174 expenditures on an annual basis
Tracking federal and New York differences as a separate line item, not an afterthought
Evaluating the cash-flow impact of differing deduction schedules
Assessing whether an amended return would produce a net benefit
Updating forecasts and estimated payments to reflect the New York-specific treatment
Accurate, jurisdiction-by-jurisdiction records are what make this manageable. Without them, the gap between federal and state numbers can lead to unexpected tax outcomes at filing time.
Frequently Asked Questions
Does New York’s rule apply to all research expenditures, or only some?
It applies to Section 174 research and experimental expenditures as defined under the state’s Fiscal Year 2027 Budget legislation, for tax years beginning on or after January 1, 2025. The scope generally tracks the same expenditures affected at the federal level.
If I already filed my New York return for 2025, do I need to amend it?
Possibly. Businesses that filed before incorporating the required New York-specific adjustments should review their returns to determine whether an amendment corrects an underpayment or captures a benefit.
Is my business likely to be affected if we’re not a traditional R&E company?
Any business incurring qualifying R&E costs and filing in New York is potentially affected, not just companies with dedicated R&E departments. Product development, engineering work, and certain software creation can all qualify.
Are there penalties for getting the New York adjustment wrong?
New York has offered some penalties and interest relief tied specifically to this legislative change, though eligibility depends on individual circumstances. Getting the adjustment right the first time is still the better outcome.
State and federal tax law don’t always move together, and New York’s approach to R&E expensing is a clear example. For manufacturers investing in product development, process improvement, and engineering work, that gap can carry real cash-flow consequences.
HBK Manufacturing Solutions works with manufacturers to identify where state and federal treatment diverge, determine what adjustments are required, and build those changes into ongoing tax planning.
If your company incurs research and development expenses and files in New York, our team can help you assess the impact and determine next steps. Contact HBK Manufacturing Solutions at 330-758-8613 or manufacturing@hbkcpa.com to schedule a consultation.
Speak to one of our professionals about your organizational needs
